ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Jun 30, 2020||ENDRA Life Sciences Submits 510(k) Application to the US FDA for TAEUS(R) Liver Device|
|Jun 23, 2020||ENDRA Life Sciences Expands IP Portfolio to 72 with Addition of Key Patents|
|Jun 08, 2020||ENDRA Life Sciences to Present at the 2020 Virtual Summer Summit|
|Jun 08, 2020||ENDRA Life Sciences Announces New Clinical Study Partnership with the Medical College of Wisconsin (MCW)|
|Jun 03, 2020||47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th|
|Day Range||0.8500 - 1.1300|
|52 Week Range||0.5990 - 2.2500|
|Bid/Ask||0.8950 / 0.9051|
|Bid/Ask Size||26,500 X 600|
|Market Cap||13.04 million|
|Shares Outstanding||14.5 million|
|Dividend/Yield||0.0000 / 0.0000%|
|P/E Ratio (TTM)||N/A|